These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21819810)

  • 1. [Post-marketing surveillance systems for psychoactive prescription drug abuse].
    Nordmann S; Frauger E; Pauly V; Rouby F; Mallaret M; Micallef J; Thirion X
    Therapie; 2011; 66(3):263-72. PubMed ID: 21819810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring risk: post marketing surveillance and signal detection.
    Dart RC
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S26-32. PubMed ID: 19748743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse.
    Butler SF; Budman SH; Licari A; Cassidy TA; Lioy K; Dickinson J; Brownstein JS; Benneyan JC; Green TC; Katz N
    Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1142-54. PubMed ID: 18932173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OPPIDUM surveillance program: 20 years of information on drug abuse in France.
    Frauger E; Moracchini C; Le Boisselier R; Braunstein D; Thirion X; Micallef J;
    Fundam Clin Pharmacol; 2013 Dec; 27(6):672-82. PubMed ID: 23510229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The consequences of drug misuse on post-marketing surveillance.
    Schifano F; Papanti GD; Orsolini L; Corkery JM
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):867-71. PubMed ID: 27095119
    [No Abstract]   [Full Text] [Related]  

  • 6. Slow-release oral morphine sulfate abuse: results of the postmarketing surveillance systems for psychoactive prescription drug abuse in France.
    Peyriere H; Eiden C; Micallef J; Lapeyre-Mestre M; Faillie JL; Blayac JP
    Eur Addict Res; 2013; 19(5):235-44. PubMed ID: 23428846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Safety signal detection by the French Addictovigilance Network: Innovative methods of investigation, examples and usefulness for public health].
    Micallef J; Jouanjus É; Mallaret M; Lapeyre Mestre M
    Therapie; 2019 Dec; 74(6):579-590. PubMed ID: 31694770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk management and post-marketing surveillance of CNS drugs.
    Henningfield JE; Schuster CR
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S56-64. PubMed ID: 19767155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prescription of psychotropic drugs; use, misuse and abuse].
    Zarifian E
    Bull Acad Natl Med; 1998; 182(7):1439-46; discussion 1446-7. PubMed ID: 9916338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correspondents in post- marketing surveillance, drug dependence surveillance, and toxicovigilance: definition and roles].
    Rioufol C; Vial T; Pulce C; Descotes J
    Therapie; 2002; 57(2):201-4. PubMed ID: 12185974
    [No Abstract]   [Full Text] [Related]  

  • 11. Example of an investigation of an "emergent" phenomenon in addiction vigilance: the case of methylphenidate.
    Micallef J; Frauger E; Palmaro A; Boucherie Q; Lapeyre Mestre M
    Therapie; 2015; 70(2):191-202. PubMed ID: 25858575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychoactive drug abuse in older adults.
    Simoni-Wastila L; Yang HK
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):380-94. PubMed ID: 17296542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
    Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
    Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk management and post-marketing surveillance of CNS drugs: an introduction.
    Balster RL; Johanson CE; Walsh SL
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S1-3. PubMed ID: 19744805
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug abuse monitoring: which pharmacoepidemiological resources at the European level?
    Lapeyre-Mestre M; Dupui M
    Therapie; 2015; 70(2):147-65. PubMed ID: 25858571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction to College on Problems of Drug Dependence special conference on risk management and post-marketing surveillance of CNS drugs.
    Schuster CR; Barthwell AG; Henningfield JE
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S4-8. PubMed ID: 19783381
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of the post-marketing authorisation studies in drug risk surveillance: specifications and methodologies.
    Tubach F; Lamarque-Garnier V; Castot A;
    Therapie; 2011; 66(4):355-62, 347-54. PubMed ID: 21851800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Psychoactive substance use during pregnancy: a review].
    Lamy S; Thibaut F
    Encephale; 2010 Feb; 36(1):33-8. PubMed ID: 20159194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current French system of post-marketing drug surveillance.
    Albengres E; Gauthier F; Tillement JP
    Int J Clin Pharmacol Ther Toxicol; 1990 Jul; 28(7):312-4. PubMed ID: 2387656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescription drug abuse.
    Finch J
    Prim Care; 1993 Mar; 20(1):231-9. PubMed ID: 8464944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.